Akt inhibition improves long‐term tumour control following radiotherapy by altering the microenvironment-Reference-Cited by-同舟云学术

Akt inhibition improves long‐term tumour control following radiotherapy by altering the microenvironment

Published:2017-10-30 Issue:12 Volume:9 Page:1646-1659
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Searle Emma J¹²³^ORCID,Telfer Brian A¹,Mukherjee Debayan²³,Forster Duncan M⁴,Davies Barry R⁵,Williams Kaye J¹⁶⁷,Stratford Ian J¹,Illidge Tim M²³^ORCID

Affiliation:

1. Division of Pharmacy and Optometry School of Health Sciences University of Manchester Manchester UK

2. Division of Cancer Sciences School of Medical Sciences University of Manchester Manchester UK

3. Christie Hospital Manchester Academic Health Sciences Centre University of Manchester Manchester UK

4. Division of Informatics, Imaging & Data Sciences School of Health Sciences University of Manchester Manchester UK

5. IMED Oncology Biotech Unit AstraZeneca Cambridge UK

6. CRUK‐EPSRC Cancer Imaging Centre in Cambridge and Manchester Cambridge UK

7. CRUK‐EPSRC Cancer Imaging Centre in Cambridge and Manchester Manchester UK

Funder

AstraZeneca

Cancer Research UK

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201707767

Reference40 articles.

1. Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .

2. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

3. Radiation oncology: a century of achievements

4. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer

5. The Phosphoinositide 3-Kinase Pathway

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations;Clinical Cancer Research;2024-04-17

2. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy;Cancer Cell;2023-07

3. Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment;International Journal of Molecular Sciences;2021-02-11

4. Akt regulates RSK2 to alter phosphorylation level of H2A.X in breast cancer;Oncology Letters;2021-01-06

5. Emerging role of tumor cell plasticity in modifying therapeutic response;Signal Transduction and Targeted Therapy;2020-10-07